Tags : GENESIS trial

BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial

Shots: The P-III GENESIS Trial involves assessing of BL-8040 + G-CSF (granulocyte colony-stimulating factor) vs G-CSF/PBO in 177 patients with multiple myeloma for the mobilization of CD34 HSCs for autologous transplantation across 25 centres The study resulted in meeting 1EP with 82% patients reached threshold ≥ 6×106 CD34 cells/kg in 2 apheresis sessions, 64% reached […]Read More

BioLineRx Annouces Positive Results for Phase 3 GENESIS Trial in

Shots:  Results of Ph 3 GENESIS trial comparing combination of BL-8040 plus G-CSF vs. G-CSF in multiple myeloma patients  GENESIS is an open-label, single-arm study with 30 patients. First 11 patients showed safety and tolerability Results: In trial 9/11 (82%) showed ≥6×106CD34 cells/kg after 2 apheresis; 7/11 (64%), showed ≥6×106 CD34 cells/kg post 1 session, […]Read More